Zacks expects $10.1 billion from Mounjaro and $5.1 billion from Zepbound, and notes Lilly plans to seek retatrutide approval in early 2027.
Recap by typeshit. Full story at TradingView.
ASU's Justin Bina told the New York Post that people starting GLP-1 drugs become willing to pay more per pound for certain proteins, even as cattle stocks hit a 75-year low.
Medicare open enrollment has started, and plan changes include newly negotiated drug prices and lower costs on some medications.
Ireland's drug pricing watchdog found Wegovy gives value for money and recommended the health service consider covering it publicly.
Prescriptions roll out in phases from the 29th, starting at 129,800 won for four weeks. Hanmi reported 9.75% average weight loss at 40 weeks in a phase 3 interim analysis.
The health committee says the plan to reach 220,000 people would cover only 6% of 2.8 million eligible patients, and suggests using digital providers.
Healio
Covers PMOS, fertility, pregnancy and menopause, and why treating obesity can help beyond the scale. A clinician explainer with little on GLP-1s.
Loading…